Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.94 INR -6.34% Market Closed
Market Cap: 525.8m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

P/E
Price to Earnings

-203.8
Current
-5.3
Median
22.1
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-203.8
=
Market Cap
525.8m INR
/
Net Income
-2.6m INR
All Countries
Close
Market Cap P/E
IN
Transgene Biotek Ltd
BSE:526139
525.8m INR -203.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -181 249.3
US
Abbvie Inc
NYSE:ABBV
316.5B USD 62.3
US
Amgen Inc
NASDAQ:AMGN
141.2B USD 33.4
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 929.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD -219.5
US
Epizyme Inc
F:EPE
94.1B EUR -471.4
AU
CSL Ltd
ASX:CSL
135.7B AUD 32
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD 16.8
US
Seagen Inc
F:SGT
39.3B EUR -54.6
NL
argenx SE
XBRU:ARGX
36B EUR -135.4
Earnings Growth P/E to Growth
IN
Transgene Biotek Ltd
BSE:526139
Average P/E: 214.7
Negative Multiple: -203.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 249.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.3
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.4
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
929.1
77%
12
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -219.5
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.4 N/A N/A
AU
CSL Ltd
ASX:CSL
32
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.4 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
N/A
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A

See Also

Discover More